#United States #New York #Prostate Cancer #Actinium #ATNM-400

Introduction

Actinium Pharmaceuticals, a leader in targeted radiotherapy development, has made a significant announcement regarding its innovative therapy, ATNM-400, for metastatic castration-resistant prostate cancer (mCRPC). The preliminary results from their Phase 1 clinical trial will be featured in an oral presentation at the upcoming European Association of Nuclear Medicine (EANM) annual congress, set to take place from October 17 to 21, 2026, in Vienna, Austria.

Details of the Presentation

The presentation will focus on the first-in-human Phase 1 dose-escalation study investigating ATNM-400, which integrates an Actinium-225 (²²⁵Ac) antibody radioconjugate that specifically targets non-PSMA antigens linked to tumor survival and treatment resistance. As this study progresses, it will evaluate the safety, biodistribution, and dosimetry related to the use of Zirconium-89-labeled ATNM-400. The researchers are utilizing serial PET imaging to monitor the drug's tumor uptake, distribution, and clearance, along with dosimetry estimates that will guide therapeutic dosing.

Statement from Actinium’s Leadership

"The early clinical results from ATNM-400 represent a crucial step forward for both Actinium and the treatment landscape for prostate cancer beyond the PSMA paradigm," stated Sandesh Seth, Chairman and CEO of Actinium Pharmaceuticals. He emphasized the importance of ATNM-400 as a pioneering targeted radiotherapy that caters to an extensive range of patients, particularly those with PSMA-low or PSMA-negative cancer types, and those not responsive to PSMA-targeting treatments.

Innovative Approach to Cancer Treatment

ATNM-400 stands out as a first-in-class therapy aiming to address the unmet needs in the mCRPC demographic. This innovative approach, distinct from traditional PSMA-targeted therapies, holds promise in expanding treatment options for patients who currently have limited alternatives. The biological basis for ATNM-400’s development is rooted in its ability to target tumors effectively while minimizing toxicity to healthy tissues, thereby adhering to Actinium's mission of enhancing cancer treatment results through precise and effective radioconjugates.

Actinium's Commitment to Advancing Healthcare

Actinium Pharmaceuticals has consistently focused on exploring advanced treatments, and ATNM-400 is well-positioned to make a notable impact in clinical oncology. The company is also progressing with additional products targeted at other oncology fields, demonstrating versatility and commitment to improving patient outcomes across various malignancies. ATNM-400's development reflects a robust pipeline strategy aimed at addressing solid tumors and hematologic malignancies alike.

Conclusion

The upcoming presentation at EANM 2026 is not only pivotal for ATNM-400 but also represents a broader step forward in cancer therapy options for mCRPC patients. The outcome of this clinical trial and subsequent findings could play a vital role in reshaping the landscape of prostate cancer treatment, potentially offering hope to those affected by this challenging condition. As Actinium Pharmaceuticals continues to innovate and transform cancer care, the healthcare community eagerly anticipates further developments from this groundbreaking company.